Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Rain Oncology to $17 from $18 and keeps a Buy rating on the shares. There were no major updates of significance in the company’s Q4 report, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RAIN:
- Rain Oncology price target raised to $19 from $12 at H.C. Wainwright
- Rain Oncology reports Q4 EPS (70c), consensus (56c)
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Rain Oncology delayed data could be positive sign, says JonesResearch